Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas
N/A
80 Years
Both
Lymphoma
Trial Information
Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas
Carmustine, cytarabine, etoposide, melphalan, and rituximab are all standard chemotherapy
drugs.
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the toss of a coin) to one of two treatment groups. Participants in one group will
receive high dose rituximab with transplantation and high dose chemotherapy. Participants
in the other group will receive standard dose rituximab with transplantation and high dose
chemotherapy. The first 10 patients enrolled on this study will have an equal chance of
being assigned to either group. After the first 10 participants are enrolled, the remaining
participants will have a higher chance of being assigned to the group that has proven to be
more effective.
All participants will have a plastic tube (catheter) inserted under their collarbone. This
catheter will be left in place for the entire treatment period. The catheter will be used
to deliver most of the drugs and for the collection and transfusion of the stem cells. When
possible, all drugs that need to be given by vein will be given using the catheter.
Stem cell collection is done on a separate study and patients will take part in this study
only after the stem cell collection is complete. You should have an adequate number of stem
cells collected and stored before you can be eligible for high-dose chemotherapy and
transplantation.
All treatment will be given at M. D. Anderson. You will be admitted to the hospital to
receive high dose chemotherapy and will stay in the hospital for 3-4 weeks. You will be
given carmustine by vein over 1 hour on Day 1. On Days 2 - 5, you will be given cytarabine
by vein over 1 hour and etoposide by vein over 3 hours. This will be repeated every 12
hours on Days 2-5. On Day 6, you will be given melphalan by vein over 30 minutes. On Day
7, the stem cells that were collected earlier will be given back to you ("transplanted")
through the catheter over 30-45 minutes.
You will also receive either high dose or standard dose rituximab by vein over 4-6 hours one
day after the transplant (Day 1) and then again 1 week later (Day 8).
You will receive G-CSF injections staring at Day 1 (one day after transplant or stem cell
infusion). These will continue our cell count reaches the appropriate level for at least 3
days in a row. Blood tests (2 teaspoons) will be done every day while you are in the
hospital to track the effects of the transplant.
You will be asked to return to M. D. Anderson at 3 months and 6 months after
transplantation, then every 6 months for 3 years, and then once a year up to 5 years from
the transplant date. At each visit you will get blood work (1-2 tablespoons), CT scans, and
other tests like bone marrow (if needed) to determine the status of your lymphoma.
This is an investigational study. All of the drugs used in this study are FDA approved and
are commercially available. Up to 100 patients will take part in this study. All will be
enrolled at M. D. Anderson.
Inclusion Criteria:
1. Patients with histologically proven diffuse large B-cell (CD20 positive) or
transformed follicular non-Hodgkin's lymphomas, that have relapsed after conventional
chemotherapy and are not eligible for protocols of higher priority
2. Patients must have chemosensitive disease to salvage chemotherapy and less than 5%
bone marrow involvement with lymphoma by gross pathologic examination
3. Age less than or equal to 80 years. There is no lower age limit for this study.
4. Zubrod performance status of less than 2
5. Negative pregnancy test in patients with child bearing potential
6. Must be willing to sign informed consent
7. Should be seronegative for HIV, hepatitis B surface antigen, hepatitis C antibody.
Exclusion Criteria:
1. Patients with known active CNS disease are excluded. Patients with prior history of
CNS disease should have a negative MRI of the brain (and/or spine if indicated) and
negative CSF cytology within 4 weeks of enrollment into the study.
2. Less than 3 weeks from last cytotoxic chemotherapy
3. Serum bilirubin > 1.5 mg/dl
4. Serum transaminases > 2X/ULN
5. Serum creatinine > 1.6 mg/dl
6. Failure to collect more than 3 x 1,000,000 CD34+ stem cells/kg body weight
7. Left ventricular ejection fraction of < 40%, unless cleared by cardiology
8. Corrected DLCO of < 50%
9. Patients who are on anticoagulants or antiplatelet agents.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Disease-free Survival (DFS)
Outcome Description:
DFS defined as time from transplantation to disease relapse, disease progression, death during remission, or last follow-up. Evaluation at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.
Outcome Time Frame:
Up to 5 years from transplant date.
Safety Issue:
Yes
Principal Investigator
Chitra M. Hosing, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UT MD Anderson Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
2004-0271
NCT ID:
NCT00472056
Start Date:
March 2005
Completion Date:
Related Keywords:
- Lymphoma
- Non-Hodgkin's Lymphoma
- Lymphoid Malignancies
- Lymphoma
- BEAM Chemotherapy
- Carmustine
- BCNU
- BiCNU
- Etoposide
- VePesid
- Cytarabine
- Cytosar
- DepoCyt
- Cytosine arabinosine hydrochloride
- Ara-C
- Melphalan
- Rituximab
- Rituxan
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
Name | Location |
|---|---|
| UT MD Anderson Cancer Center | Houston, Texas 77030 |
